Underutilization of angiotensin-converting enzyme inhibitors in high-risk blacks: A case of missed opportunities

Journal of Clinical Hypertension

Volumn 11, Issue 11, 2009, Pages 648-650

  Ferdinand, Keith C ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOPROLOL SUCCINATE; RAMIPRIL; THIAZIDE DIURETIC AGENT;

AFRICAN AMERICAN; ANGIOCARDIOGRAPHY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG UTILIZATION; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

AFRICAN AMERICANS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; HUMANS; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70449346352     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00187.x     Document Type: Note

References (14)

1. Papademetriou V, Kaoutzanis C, Dumas M. Protective effects of angiotensin-converting-enzyme inhibitors in high risk African-American men with coronary heart disease. J Clin Hypertens. 2009, doi
2. National Vital Statistics Reports. 2007, US National Center for Health Statistics, Vol 55, No 19, August 21
3. Cooper RS, Wolf-Maier K, Luke A. An international comparative study of blood pressure in populations of European vs African descent. BMC Med. 2005, 3:2.
4. Clark LT, Ferdinand KC, Flack JM. Coronary heart disease in African Americans. Heart Dis. 2001, 3:97-108.
5. Sehgal AR. Overlap between Whites and Blacks in response to antihypertensive drugs. Hypertension. 2004, 43:566-572.
6. Ferdinand KC. Recommendations for the management of special populations: racial and ethnic populations. Am J Hypertens 2003, 16:50S-54S. 11, pt 2
7. Alderman MH, Cohen HW, Sealey JE. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004, 17:1-7.
8. Chobanian AV, Bakris GL, Black HR. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
9. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive=20and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
10. Wright JT, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002, 288:2421-2431.
11. Exner DV, Dries DL, Domanski MJ. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351-1357.
12. Jamerson K, Weber MA, Bakris GL. Benzaperil plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
13. Pepine CJ, Handberg EM, Cooper-DeHoff RM. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The INternational VErapamil Sr-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003, 290:2805-2816.
14. King ML. Pathologies of Power: Health, Human Rights, and the New War on the Poor 2004, as quoted in Farmer, P, Berkeley & Los Angeles, CA, University of CA